<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03483545</url>
  </required_header>
  <id_info>
    <org_study_id>000324</org_study_id>
    <nct_id>NCT03483545</nct_id>
  </id_info>
  <brief_title>Menopur And Rekovelle Combination Study</brief_title>
  <acronym>MARCS</acronym>
  <official_title>An Exploratory Study to Evaluate a Mixed Protocol of Menopur (Highly Purified Human Menopausal Gonadotropin) and REKOVELLE (Follitropin Delta) for Controlled Ovarian Stimulation in IVF (in Vitro Fertilization)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr François Bissonnette</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Create Fertility Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Olive Fertility Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannam Fertility Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinique Ovo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposes to evaluate the effect of adding HP-hMG (Menopur) to follitropin delta in&#xD;
      a &quot;mixed protocol&quot; regimen, using an individualized, fixed dose of follitropin delta based on&#xD;
      the established algorithm, combined with a variable, adjustable dose of Menopur based on body&#xD;
      weight and ovarian reserve.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The initial dose of follitropin delta will be determined at enrolment by the analysis of&#xD;
      serum AMH on days 2 to 5 of the menstrual cycle preceding the IVF treatment cycle and body&#xD;
      weight in Kg The initial dose of HP-hMG to be added on top of follitropin delta will be&#xD;
      determined at enrolment by the total follitropin delta dose and body weight in Kg&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2018</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the number of utilizable blastocysts on Day 5 or Day 6 of embryo culture</measure>
    <time_frame>6 days of embryo culture</time_frame>
    <description>Utilizable blastocyst is defined as embryo at day 5 or 6 suitable for transfer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine dosage of REKOVELLE and Menopur in a mixed protocol</measure>
    <time_frame>up to 20 days</time_frame>
    <description>Evaluate the effect of adding HP-hMG (Menopur) to follitropin delta (REKOVELLE) during IVF stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety profile of the REKOVELLE - Menopur mixed protocol algorithm</measure>
    <time_frame>up to 20 days</time_frame>
    <description>The safety profile is the proportion of women with early and late OHSS and/or preventive interventions for early OHSS (i.e., triggering with GnRH agonist, use of dopamine agonist, conversion of planned fresh transfer into a freeze-all). OHSS is defined as an iatrogenic complication that occurs mainly due to ovarian overstimulation by gonadotropins.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Fertility Disorders</condition>
  <arm_group>
    <arm_group_label>Follitropin delta and HP-hMG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Follitropin delta combined with highly purified human menopausal gonadotrophin</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Follitropin delta and HP-hMG</intervention_name>
    <description>Follitropin delta dose will be determined by AMG and weight in Kg. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight in Kg</description>
    <arm_group_label>Follitropin delta and HP-hMG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women 18 to 40 years of age undergoing their first IVF/ICSI cycle&#xD;
&#xD;
          -  Diagnosed with unexplained infertility, tubal infertility, endometriosis stage I/II,&#xD;
             or with partners diagnosed with male factor infertility&#xD;
&#xD;
          -  Regular menstrual cycles of 24-35 days&#xD;
&#xD;
          -  Presence of both ovaries&#xD;
&#xD;
          -  Early follicular phase FSH serum concentration &lt;10 IU/L measured between Day 2 to Day&#xD;
             5 of menstrual cycle within the previous 12 months&#xD;
&#xD;
          -  Ejaculated sperm (fresh or frozen) for insemination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to consent&#xD;
&#xD;
          -  Endometriosis stage III and IV&#xD;
&#xD;
          -  High risk of OHSS (AMH ≥ 35 pmol/L)&#xD;
&#xD;
          -  History of recurrent miscarriages defined as ≥ 3 consecutive losses&#xD;
&#xD;
          -  Women undergoing egg donation&#xD;
&#xD;
          -  Women participating in any other research project&#xD;
&#xD;
          -  Use of hormonal preparations (except for thyroid medication) during the last menstrual&#xD;
             cycle&#xD;
&#xD;
          -  Hypersensitivity to follitropin delta and/or HP-hMG&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Bissonnette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Ovo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clifford Librach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CReATe Fertility Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Hannam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannam Fertility Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Al Yuzpe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Olive Fertility Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Olive Fertility Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannam Fertility Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4W 3R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CReATe Fertility Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Ovo</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4P 2S4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Clinique Ovo</investigator_affiliation>
    <investigator_full_name>Dr François Bissonnette</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ovarian Response</keyword>
  <keyword>In vitro fertilization</keyword>
  <keyword>Controlled ovarian stimulation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

